Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Gibson

Pain Medicine Madison, WI Medical Doctor

NPI 1356737464 CMS profile 1401626

700 S Park St, Fl 2, Madison, WI 53715

Open in the dashboard

General payments

$7,895

116 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Gibson of Madison, WI is reported in the CMS Open Payments database as having received $7,895 across 116 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $55 1
2024 General $583 7
2023 General $2,519 14
2022 General $1,408 35
2021 General $1,836 23
2020 General $772 19
2019 General $723 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Gibson
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Michael Gibson were reported at $55. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Michael Gibson Pain Medicine median Middle half National median
2019 $723 $498 $126–$1,682 $163
2020 $772 $284 $80–$910 $114
2021 $1,836 $399 $112–$1,219 $132
2022 $1,408 $455 $137–$1,484 $149
2023 $2,519 $484 $128–$1,495 $160
2024 $583 $498 $131–$1,540 $164
2025 $55 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,155 71 payments
  2. SPR Therapeutics, Inc $2,035 12 payments
  3. Nalu Medical, Inc. $914 7 payments
  4. Foundation Fusion Solutions, LLC $671 5 payments
  5. Boston Scientific Corporation $459 8 payments
  6. Medtronic, Inc. $234 5 payments
  7. Medtronic USA, Inc. $233 4 payments
  8. Vertiflex, Inc. $99 1 payment
  9. ViiV Healthcare Company $55 1 payment
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $20 1 payment
  11. Other $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,649 102 payments
  2. Travel and Lodging $3,197 12 payments
  3. Education $34 1 payment
  4. Entertainment $16 1 payment
Products named General payments · program years 2019–2025
  1. SPRINT PNS System $2,035 12 payments
  2. Proclaim IPG $1,668 18 payments
  3. Nalu Neurostimulation System $914 7 payments
  4. Proclaim Family of SCS IPGs $684 22 payments
  5. PROCLAIM $608 25 payments
  6. SPECTRA WAVEWRITER $342 7 payments
  7. RESTORE $162 3 payments
  8. VANTA ADAPTIVESTIM $159 3 payments
  9. SUPERION $117 1 payment
  10. ETERNA $101 1 payment
  11. Other $437 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

318

Median for Pain Management: 951

Drug cost

$2,806

Median for Pain Management: $26,034

Branded share of claims

9.1%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 64 $847
Duloxetine Hcl Generic 30 $523
Gabapentin Generic 40 $430
Tizanidine Hcl Generic 31 $388
Baclofen Generic 32 $205
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 29 $190
Tramadol Hcl Generic 53 $127
Oxycodone Hcl Generic 12 $58
Cephalexin Generic 27 $40

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$133,737

Of which drugs: $1,459

Medicare patients

301

Average age 74

Services billed

12,157

164 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Diabetes 30%
Ischemic heart disease 27%
Depression 26%
Chronic kidney disease 25%
Heart failure 18%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 119 10,480 $1,061
Injection, methylprednisolone acetate, 80 mg J1040 Office 31 31 $238
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 134 289 $83
Injection, methylprednisolone acetate, 40 mg J1030 Office 12 13 $45
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 32 350 $32

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

116 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record